We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...
On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...
The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results